With a recent clinical hold for macrophage-directed therapies, the field is seeking clinical validation to ease concerns over safety and efficacy of these therapies, and to boost funding to support these trials. The macrophage field have been eagerly waiting for the return of the Macrophage-directed Therapies Summit to share hotly-anticipated clinical updates, next-generation approaches, methods to overcome preclinical and clinical hurdles as well as novel targets.

Turbocharge and seize control of the mighty macrophage:

• Optimize preclinical model translatability to improve the transfer to the clinic with Macomics and evaluate whether a monotherapy or combination approach is for you with OSE Immunotherapeutics and Ichnos Sciences
• Explore the latest approaches beyond CD47 from including exosome-mediated targeting, in vivo CAR-M, as well as novel targets and more with Codiak Biosciences, Carisma Therapeutics, Pheast Therapeutics and ImCheck Thearpeutics
• Take a deep dive into macrophage-related biomarkers to leverage pharmacodynamics, optimize patient selection, control macrophage function and boost clinical development by establishing best-in-class predictive, response and macrophage phenotype biomarkers in our NEW Biomarker Bootcamp
• As a continuously growing and developing field, 2022 brings 11 new companies and a 68% brand-new speaker faculty sharing the latest insights, along with piles of new and unpublished preclinical and clinical data